Wednesday, April 12th 2017
Vaxinano has obtained funding from the British government to evaluate its technology for a Zika vaccine
The British Department of Health, through the Innovate-UK SBRI funding competition has awarded funding to Vaxinano for the development of an innovative and efficient vaccine against the Zika virus.
This funding supports projects seeking to develop candidate vaccines and vaccine platform technologies at the preclinical stage to enable an effective and rapid response during future outbreaks of disease. The UK Vaccine Network has identified 12 pathogens as a priority, including Zika.
“This is a unique opportunity to demonstrate the extraordinary power of our technology” said Vincent Lemonnier, CEO of Vaxinano.